Fred Aslan
Company: Artiva Biotherapeutics, Inc
Job title: President & Chief Executive Officer
Bio:
Fred Aslan, M.D. brings two decades of leadership in the life sciences industry as an executive, investor, and entrepreneur. Most recently, he served as President and Chief Business Officer at Vividion Therapeutics, where he led Series B financing and a $135 million collaboration with Roche. Previously, he spent 12 years with Venrock, co-founding Receptos and investing in Zeltiq and Fate Therapeutics. He also served as CEO of Adavium Medical in Brazil, scaling the company to 350 employees and over $40 million in revenue. Dr. Aslan holds degrees from Duke, Yale, and Harvard.
Seminars:
Leveraging NK Therapies to Advance Autoimmune Cell Therapy Safety 11:30 am
Highlight the rationale and potential advantages of utilizing a non-genetically modified NK cell therapy in combination with monoclonal antibodies in autoimmune diseases Explore clinical data demonstrating that NK cell therapies can drive deep B-cell depletion in autoimmune disease while avoiding side effects inherent in CAR-T and TCE therapies Highlight a framework for selecting indications for…Read more
day: Conference Day One Teal Track P1
Chair’s Opening Remarks 8:30 am
day: Conference Day 1 P1
Industry Leaders Fireside Chat: Evaluating CAR-T in Comparison to Emerging Modalities to Refine Autoimmune Therapies Through Strategic Modality Selection 8:40 am
Explore the efficacy of differing modalities to identify opportunities where we can learn from other modalities Compare modalities in their affinity for targeting autoreactive cells to minimize side-effects and enhance safety Identify autoimmune indications where CD-19-CARs are suboptimal to spotlight opportunities for alternative therapeutic modalitiesRead more
day: Conference Day 1 P1
Chair’s Opening Remarks 8:55 am
day: Conference Day Two P1
Panel Discussion: Re-Evaluating Lymphodepletion to Improve Patient Access & Limit Therapeutic Side Effects 9:00 am
Consider the need for lymphodepletion on cell therapy to identify opportunities to remove preconditioning from therapies Identify characteristics of therapies that avoid lymphodepletion to pinpoint opportunities to broaden their benefits to more therapies Examine the impact of lymphodepletion on patient recruitment and accessibilityRead more
day: Conference Day Two P1